These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 33642983)

  • 1. Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases.
    Minakawa EN; Nagai Y
    Front Neurosci; 2021; 15():621996. PubMed ID: 33642983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases.
    Takeuchi T; Nagai Y
    Brain Sci; 2017 Oct; 7(10):. PubMed ID: 29019918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
    Nagai Y; Popiel HA
    Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation.
    Minakawa EN; Popiel HA; Tada M; Takahashi T; Yamane H; Saitoh Y; Takahashi Y; Ozawa D; Takeda A; Takeuchi T; Okamoto Y; Yamamoto K; Suzuki M; Fujita H; Ito C; Yagihara H; Saito Y; Watase K; Adachi H; Katsuno M; Mochizuki H; Shiraki K; Sobue G; Toda T; Wada K; Onodera O; Nagai Y
    Brain; 2020 Jun; 143(6):1811-1825. PubMed ID: 32436573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].
    Nagai Y
    Rinsho Shinkeigaku; 2009 Nov; 49(11):913-6. PubMed ID: 20030247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
    Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
    Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide-based therapeutic approaches for treatment of the polyglutamine diseases.
    Takeuchi T; Popiel HA; Futaki S; Wada K; Nagai Y
    Curr Med Chem; 2014; 21(23):2575-82. PubMed ID: 24533807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disruption of the toxic conformation of the expanded polyglutamine stretch leads to suppression of aggregate formation and cytotoxicity.
    Popiel HA; Nagai Y; Onodera O; Inui T; Fujikake N; Urade Y; Strittmatter WJ; Burke JR; Ichikawa A; Toda T
    Biochem Biophys Res Commun; 2004 May; 317(4):1200-6. PubMed ID: 15094397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A toxic monomeric conformer of the polyglutamine protein.
    Nagai Y; Inui T; Popiel HA; Fujikake N; Hasegawa K; Urade Y; Goto Y; Naiki H; Toda T
    Nat Struct Mol Biol; 2007 Apr; 14(4):332-40. PubMed ID: 17369839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of protein misfolding/aggregation using polyglutamine binding peptide QBP1 as a therapy for the polyglutamine diseases.
    Popiel HA; Takeuchi T; Burke JR; Strittmatter WJ; Toda T; Wada K; Nagai Y
    Neurotherapeutics; 2013 Jul; 10(3):440-6. PubMed ID: 23504628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interplay between PolyQ and protein context delays aggregation by forming a reservoir of protofibrils.
    Bulone D; Masino L; Thomas DJ; San Biagio PL; Pastore A
    PLoS One; 2006 Dec; 1(1):e111. PubMed ID: 17205115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease.
    Adegbuyiro A; Sedighi F; Pilkington AW; Groover S; Legleiter J
    Biochemistry; 2017 Mar; 56(9):1199-1217. PubMed ID: 28170216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surface plasmon resonance characterization of specific binding of polyglutamine aggregation inhibitors to the expanded polyglutamine stretch.
    Okamoto Y; Nagai Y; Fujikake N; Akiko Popiel H; Yoshioka T; Toda T; Inui T
    Biochem Biophys Res Commun; 2009 Jan; 378(3):634-9. PubMed ID: 19061859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Aggregation Inhibitor Peptide QBP1 as a Therapeutic Molecule for the Polyglutamine Neurodegenerative Diseases.
    Popiel HA; Burke JR; Strittmatter WJ; Oishi S; Fujii N; Takeuchi T; Toda T; Wada K; Nagai Y
    J Amino Acids; 2011; 2011():265084. PubMed ID: 22312459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why Is Arginine the Only Amino Acid That Inhibits Polyglutamine Monomers from Taking on Toxic Conformations?
    Tanimoto S; Okumura H
    ACS Chem Neurosci; 2024 Jul; ():. PubMed ID: 39009034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Nanomedicines for Polyglutamine-Based Neurodegenerative Diseases.
    Lee LKC; Leong LI; Liu Y; Luo M; Chan HYE; Choi CHJ
    Mol Pharm; 2021 Feb; 18(2):610-626. PubMed ID: 32584043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of RNA-induced toxicity in CAG repeat disorders.
    Nalavade R; Griesche N; Ryan DP; Hildebrand S; Krauss S
    Cell Death Dis; 2013 Aug; 4(8):e752. PubMed ID: 23907466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset.
    Sugaya K; Matsubara S; Kagamihara Y; Kawata A; Hayashi H
    PLoS One; 2007 Jul; 2(7):e635. PubMed ID: 17653262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of molecular chaperones as a therapeutic strategy for the polyglutamine diseases.
    Nagai Y; Fujikake N; Popiel HA; Wada K
    Curr Pharm Biotechnol; 2010 Feb; 11(2):188-97. PubMed ID: 20166962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration.
    Tenchov R; Sasso JM; Zhou QA
    ACS Chem Neurosci; 2024 Jul; ():. PubMed ID: 38996083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.